NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 68.03.
Share Price | ₹14,864.3 | Nov 19,2024 |
Market Cap | ₹19,026.3 Cr | |
Earnings-TTM | ₹279.7 Cr | TTM-Consolidated Results |
Price/Earnings | 68.03x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹19,026.3 Cr] as on Nov 19,2024
(/) Earnings [ ₹279.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 68.03x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 68.03 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 23.45x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 22.43x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2021 at 33.22x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NEULAND LABORATORIES | 279.67 | 68.03 | 19,026.3 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 38.30 | 426,518.0 |
CIPLA LTD | 4,485.22 | 26.39 | 118,368.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 18.43 | 99,671.4 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.10 | 95,013.6 |
DIVIS LABORATORIES LTD | 1,836.00 | 86.40 | 158,636.0 |
MANKIND PHARMA LTD | 2,124.86 | 48.13 | 102,273.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 58.31 | 105,072.0 |
LUPIN LTD | 2,651.94 | 35.15 | 93,214.9 |
AUROBINDO PHARMA LTD | 3,598.83 | 19.69 | 70,869.4 |
ABBOTT INDIA LTD | 1,284.66 | 44.90 | 57,681.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.43x |
Max industry PE | 86.40x |
Median industry PE | 38.30x |
Average industry PE | 42.35x |
You may also like the below Video Courses